I was listening to a talk from a leading nanoparticle researcher. He basically said that making new nanoparticles and characterising them is great for writing papers but they all fail actual testing as therapeutic delivery devices. In oncology there are kinda only two nanoparticle therapies - Abraxane, which is a well known chemotherapy drug bound to albumin; liposomal doxorubicin, an encapsulated form of another well known chemotherapy drug. They have been around a while and they are not exactly game changing, extending survival a modest amount at best. Nanoparticles are overrated from where I sit, as are University press releases.<p>On the other hand, antibody based therapies are amazing revolutionary drugs in oncology. Chief among them is Keytruda which has improved the lives of so many patients and has $2billion in sales every <i>month</i> and rising. Most recently, sticking chemotherapy drugs or radioisotopes on the end of antibodies (or smaller antibody like proteins) has shown great results as a delivery vehicle. Are these ‘nanoparticles’? No, just actual drugs that work.